Sex Hormones and Orthostatic Tolerance
Primary Purpose
Orthostatic Intolerance
Status
Completed
Phase
Phase 2
Locations
United States
Study Type
Interventional
Intervention
Ganirelix acetate
17β-Oestradiol
Progesterone
Sponsored by
About this trial
This is an interventional basic science trial for Orthostatic Intolerance
Eligibility Criteria
Inclusion Criteria:
- Healthy, English-speaking non-smoking women age 18- 34 with regular menses
Exclusion Criteria:
Gynecologic:
- current or past estrogen-dependent neoplasia,
- unexplained vaginal bleeding,
- history of uterine fibroids,
- current pregnancy,
- known or suspected breast or uterine cancer,
- partial or complete hysterectomy
Cardiac:
- myocardial infarction, ventricle tachycardia or fibrillation,
- angina,
- valvular disease,
- congestive heart failure, orthopnea, paroxysmal nocturnal dyspnea,
- current arrhythmias,
- prosthetic valves
Pulmonary:
- current cigarette smokers, or pipe or cigar smokers,
- chronic obstructive pulmonary disease,
- adult asthma,
- dyspnea on exertion,
- current bronchitis, pneumonia, or tuberculosis,
- lung carcinoma,
- pulmonary embolus, recent
Vascular:
- claudication or history of peripheral vascular disease,
- abdominal or thoracic aortic aneurysm, or repair of same,
- cerebral aneurysm, vascular malformations,
- hypertension, systolic or diastolic, or strong family history of hypertension
Gastrointestinal:
- GI malignancy,
- hepatitis, current,
- splenomegaly from any cause,
- Cholecystitis,
- current diverticulosis or diverticulitis, inflammatory bowel disease, ulcerative colitis, Crohn's Disease,
- previous gastrointestinal surgery
- Infectious Disease: any intercurrent infection
Hematologic/Oncologic:
- receiving chemotherapy or radiation therapy,
- any metastatic malignancy,
- anemia (hematocrit < 35),
- thrombocytopenia or thrombocytosis,
- neutropenia,
- hematologic malignancy,
- bleeding dyscrasia
Neurologic:
- history of cerebral vascular accident with any neurologic sequels,
- uncontrolled seizures (e.g. more than 1 seizure/year),
- transient ischemic attacks,
- dementia,
- neurologic conditions producing dyscoordination, peripheral neuropathy, or myopathy,
- severe migraine headaches
Endocrine:
- diabetes mellitus,
- any untreated endocrinopathy
Renal:
- chronic renal disease,
- any history of renal disease or impairment,
- current urinary tract infection
Musculoskeletal:
- inflammatory arthritis history (e.g., rheumatoid, psoriatic, Reiters),
- any history of pathologic fractures, including vertebral compression fractures
Pharmacologic:
- any illegal drug use,
- alcohol use greater than an average of 4 oz/day over 30 days,
- coumadin or heparin use,
- current systemic antifungal use
Sites / Locations
- John B. Pierce Laboratory
Arms of the Study
Arm 1
Arm 2
Arm 3
Arm Type
Experimental
Experimental
Experimental
Arm Label
Ganirelix acetate
17β-Oestradiol, E2
Progesterone
Arm Description
Subjects were given 250 μg in 0.5ml normal saline for 16 days. (Organon, Roseland, NJ, USA)
The same women added 17β-Oestradiol, E2; 0.2 mg day-1 patch (Vivelle; CIBA Pharmaceuticals, Summit, NJ) for days 4-16.
The same women added progesterone (P4, 200 mg day-1 Prometrium, oral, Solvay Pharmaceuticals, Marietta, GA, USA) on days 13-16.
Outcomes
Primary Outcome Measures
Orthostatic Tolerance
We used a measure called cumulative stress index to determine orthostatic tolerance, which is the amount of time at a level of negative pressure each subject can maintain before feeling as if she is going to pass out. This is calculated by multiplying the pressure in mm Hg by the time in min.
Baroreceptor Function
This is a measure of how the body responds to changes in pressure induced by changes in position such as sitting, lying standing. The pressure changes are induced by gravity. The measurement described below to assess baroreceptor function is units of change in forearm vascular resistance for a given change in lower body negative pressure. This allows us to determine how good the body is at sending signals to the periphery to respond to postural changes.
Baroreflex sensitivity is defined as the change in interbeat interval (IBI) in milliseconds per unit change in BP. For example, when the BP rises by 10 mmHg and IBI increases by 100 ms, BRS would be 100/10 = 10 ms/mmHg.
Skin Microvascular Responses
Changes in blood flow in the small vessel in the skin are measured in response to sequential heat and drug stimulation. It is measured in volts, and then corrected for a maximum level and expressed as "% max." This is measured with a Laser Doppler probes, which measures volts.
Secondary Outcome Measures
Full Information
NCT ID
NCT01153581
First Posted
June 28, 2010
Last Updated
November 15, 2018
Sponsor
Yale University
Collaborators
National Heart, Lung, and Blood Institute (NHLBI)
1. Study Identification
Unique Protocol Identification Number
NCT01153581
Brief Title
Sex Hormones and Orthostatic Tolerance
Official Title
Sex Hormones and Orthostatic Tolerance
Study Type
Interventional
2. Study Status
Record Verification Date
November 2018
Overall Recruitment Status
Completed
Study Start Date
February 2006 (undefined)
Primary Completion Date
December 2012 (Actual)
Study Completion Date
May 2013 (Actual)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Yale University
Collaborators
National Heart, Lung, and Blood Institute (NHLBI)
4. Oversight
Data Monitoring Committee
No
5. Study Description
Brief Summary
This study is designed to determine the causes of "orthostatic intolerance" which occurs more commonly in women than in men. Orthostatic tolerance is the ability to remain standing up right for long periods of time, or to avoid dizziness when moving to standing from a seated or lying position.
Detailed Description
In this study we are interested in determining the impact of female reproductive hormones (estrogen and progesterone) on orthostatic tolerance (described above) so we administer these hormones to participants. We also test participants' orthostatic tolerance in our laboratory and use this information to place subjects into groups.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Orthostatic Intolerance
7. Study Design
Primary Purpose
Basic Science
Study Phase
Phase 2
Interventional Study Model
Single Group Assignment
Masking
None (Open Label)
Allocation
Non-Randomized
Enrollment
109 (Actual)
8. Arms, Groups, and Interventions
Arm Title
Ganirelix acetate
Arm Type
Experimental
Arm Description
Subjects were given 250 μg in 0.5ml normal saline for 16 days. (Organon, Roseland, NJ, USA)
Arm Title
17β-Oestradiol, E2
Arm Type
Experimental
Arm Description
The same women added 17β-Oestradiol, E2; 0.2 mg day-1 patch (Vivelle; CIBA Pharmaceuticals, Summit, NJ) for days 4-16.
Arm Title
Progesterone
Arm Type
Experimental
Arm Description
The same women added progesterone (P4, 200 mg day-1 Prometrium, oral, Solvay Pharmaceuticals, Marietta, GA, USA) on days 13-16.
Intervention Type
Drug
Intervention Name(s)
Ganirelix acetate
Other Intervention Name(s)
Antagon
Intervention Description
Ganirelix acetate: .25 ml/day by subcutaneous injection
Intervention Type
Drug
Intervention Name(s)
17β-Oestradiol
Other Intervention Name(s)
17 beta estradiol, estradiol
Intervention Description
17 beta estradiol: 0.2 mg/day (patches)
Intervention Type
Drug
Intervention Name(s)
Progesterone
Other Intervention Name(s)
P4, Prometrium
Intervention Description
progesterone, 200 mg day-1 oral
Primary Outcome Measure Information:
Title
Orthostatic Tolerance
Description
We used a measure called cumulative stress index to determine orthostatic tolerance, which is the amount of time at a level of negative pressure each subject can maintain before feeling as if she is going to pass out. This is calculated by multiplying the pressure in mm Hg by the time in min.
Time Frame
2 months
Title
Baroreceptor Function
Description
This is a measure of how the body responds to changes in pressure induced by changes in position such as sitting, lying standing. The pressure changes are induced by gravity. The measurement described below to assess baroreceptor function is units of change in forearm vascular resistance for a given change in lower body negative pressure. This allows us to determine how good the body is at sending signals to the periphery to respond to postural changes.
Baroreflex sensitivity is defined as the change in interbeat interval (IBI) in milliseconds per unit change in BP. For example, when the BP rises by 10 mmHg and IBI increases by 100 ms, BRS would be 100/10 = 10 ms/mmHg.
Time Frame
2 months
Title
Skin Microvascular Responses
Description
Changes in blood flow in the small vessel in the skin are measured in response to sequential heat and drug stimulation. It is measured in volts, and then corrected for a maximum level and expressed as "% max." This is measured with a Laser Doppler probes, which measures volts.
Time Frame
2 months
10. Eligibility
Sex
Female
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
34 Years
Accepts Healthy Volunteers
Accepts Healthy Volunteers
Eligibility Criteria
Inclusion Criteria:
Healthy, English-speaking non-smoking women age 18- 34 with regular menses
Exclusion Criteria:
Gynecologic:
current or past estrogen-dependent neoplasia,
unexplained vaginal bleeding,
history of uterine fibroids,
current pregnancy,
known or suspected breast or uterine cancer,
partial or complete hysterectomy
Cardiac:
myocardial infarction, ventricle tachycardia or fibrillation,
angina,
valvular disease,
congestive heart failure, orthopnea, paroxysmal nocturnal dyspnea,
current arrhythmias,
prosthetic valves
Pulmonary:
current cigarette smokers, or pipe or cigar smokers,
chronic obstructive pulmonary disease,
adult asthma,
dyspnea on exertion,
current bronchitis, pneumonia, or tuberculosis,
lung carcinoma,
pulmonary embolus, recent
Vascular:
claudication or history of peripheral vascular disease,
abdominal or thoracic aortic aneurysm, or repair of same,
cerebral aneurysm, vascular malformations,
hypertension, systolic or diastolic, or strong family history of hypertension
Gastrointestinal:
GI malignancy,
hepatitis, current,
splenomegaly from any cause,
Cholecystitis,
current diverticulosis or diverticulitis, inflammatory bowel disease, ulcerative colitis, Crohn's Disease,
previous gastrointestinal surgery
Infectious Disease: any intercurrent infection
Hematologic/Oncologic:
receiving chemotherapy or radiation therapy,
any metastatic malignancy,
anemia (hematocrit < 35),
thrombocytopenia or thrombocytosis,
neutropenia,
hematologic malignancy,
bleeding dyscrasia
Neurologic:
history of cerebral vascular accident with any neurologic sequels,
uncontrolled seizures (e.g. more than 1 seizure/year),
transient ischemic attacks,
dementia,
neurologic conditions producing dyscoordination, peripheral neuropathy, or myopathy,
severe migraine headaches
Endocrine:
diabetes mellitus,
any untreated endocrinopathy
Renal:
chronic renal disease,
any history of renal disease or impairment,
current urinary tract infection
Musculoskeletal:
inflammatory arthritis history (e.g., rheumatoid, psoriatic, Reiters),
any history of pathologic fractures, including vertebral compression fractures
Pharmacologic:
any illegal drug use,
alcohol use greater than an average of 4 oz/day over 30 days,
coumadin or heparin use,
current systemic antifungal use
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Nina Stachenfeld, PhD
Organizational Affiliation
Yale University
Official's Role
Principal Investigator
Facility Information:
Facility Name
John B. Pierce Laboratory
City
New Haven
State/Province
Connecticut
ZIP/Postal Code
06519
Country
United States
12. IPD Sharing Statement
Plan to Share IPD
Undecided
IPD Sharing Plan Description
Our data are stored in locked files, and our spreadsheets and raw data are available should they be requested
Learn more about this trial
Sex Hormones and Orthostatic Tolerance
We'll reach out to this number within 24 hrs